MSFT 417.14 0.9731% AAPL 229.0 -0.3438% NVDA 119.37 1.5137% GOOGL 163.38 0.989% GOOG 165.11 1.0465% AMZN 178.5 3.7067% META 521.31 0.5963% AVGO 162.82 3.7533% TSLA 214.11 3.7958% TSM 171.7 1.5075% LLY 960.02 2.1081% V 276.37 0.7473% JPM 224.8 1.1656% UNH 590.2 -0.2316% NVO 139.16 1.1926% WMT 77.23 1.0599% LVMUY 149.005 -0.3844% XOM 117.94 -0.1608% LVMHF 745.0 -0.4011% MA 483.34 0.5283%
Last update at 2024-09-05T06:10:00Z
Healius Limited's (ASX:HLS) Intrinsic Value Is Potentially 97% Above Its Share Price
Mon 01 Aug 22, 01:42 AMShould You Investigate Healius Limited (ASX:HLS) At AU$3.70?
Sat 16 Jul 22, 10:27 PMWill Weakness in Healius Limited's (ASX:HLS) Stock Prove Temporary Given Strong Fundamentals?
Tue 28 Jun 22, 02:42 AMThere's No Escaping Healius Limited's (ASX:HLS) Muted Earnings
Fri 10 Jun 22, 12:46 AMWhat Kind Of Investors Own Most Of Healius Limited (ASX:HLS)?
Sun 22 May 22, 11:49 PMInvestors in Healius (ASX:HLS) have made a decent return of 48% over the past three years
Wed 04 May 22, 10:46 PMBreakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Income before tax | -397.30000M | 416.90M | 167.80M | 46.40M | 83.20M |
Minority interest | - | - | - | - | - |
Net income | -367.80000M | 307.90M | 43.70M | -70.50000M | 55.90M |
Selling general administrative | 864.30M | 951.40M | 856.30M | 838.20M | 1137.60M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 1483.20M | 2019.50M | 1630.10M | 1381.30M | 1598.00M |
Reconciled depreciation | 277.20M | 278.50M | 247.30M | 218.00M | 68.70M |
Ebit | 34.10M | 432.40M | 221.40M | 56.50M | 117.40M |
Ebitda | 311.30M | 710.90M | 468.70M | 274.50M | 186.10M |
Depreciation and amortization | 277.20M | 278.50M | 247.30M | 218.00M | 68.70M |
Non operating income net other | - | - | - | - | - |
Operating income | 98.10M | 484.40M | 270.80M | 86.10M | 117.40M |
Other operating expenses | 263.30M | 775.30M | 672.60M | 662.10M | 1692.90M |
Interest expense | 28.60M | 15.50M | 53.60M | 0.10M | 34.20M |
Tax provision | -17.30000M | 122.90M | 101.50M | -25.60000M | 24.80M |
Interest income | 62.30M | 50.50M | 62.90M | 52.40M | 25.10M |
Net interest income | -62.30000M | -50.50000M | -87.60000M | 0.10M | -34.20000M |
Extraordinary items | 12.20M | 13.90M | -22.60000M | -142.50000M | -1.90000M |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -17.30000M | 122.90M | 101.50M | -25.60000M | 27.30M |
Total revenue | 1706.90M | 2336.20M | 1900.70M | 1584.60M | 1804.50M |
Total operating expenses | 1385.10M | 1531.60M | 1388.20M | 1307.90M | 1486.40M |
Cost of revenue | 223.70M | 316.70M | 270.60M | 203.30M | 206.50M |
Total other income expense net | -433.10000M | -20.50000M | 13.50M | 2.60M | -34.20000M |
Discontinued operations | 12.20M | 13.90M | -22.60000M | -142.50000M | -1.90000M |
Net income from continuing ops | -380.00000M | 294.00M | 66.30M | 72.00M | 55.90M |
Net income applicable to common shares | -367.80000M | 307.90M | 43.70M | -70.50000M | 55.30M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Total assets | 3653.20M | 4136.80M | 3782.20M | 4566.50M | 3350.80M |
Intangible assets | 73.10M | 75.20M | 76.30M | 79.30M | 77.90M |
Earning assets | - | - | - | - | - |
Other current assets | 31.60M | 70.80M | 40.80M | 26.10M | 31.50M |
Total liab | 2147.00M | 2215.20M | 1924.90M | 2635.20M | 1295.40M |
Total stockholder equity | 1506.20M | 1921.60M | 1857.30M | 1931.30M | 2055.40M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 0.90M | 5.70M | 52.30M | 447.90M | 6.90M |
Common stock | 2421.00M | 2422.90M | 2572.00M | 2672.30M | 2671.10M |
Capital stock | 2421.00M | 2422.90M | 2572.00M | 2672.30M | 2671.10M |
Retained earnings | -923.30000M | -521.20000M | -731.60000M | -737.60000M | -608.10000M |
Other liab | 14.40M | 18.60M | 22.50M | 74.20M | 96.50M |
Good will | 1897.50M | 2344.30M | 2042.30M | 2040.20M | 2482.50M |
Other assets | 87.90M | 74.60M | 82.20M | 82.40M | 118.20M |
Cash | 115.30M | 81.30M | 70.10M | 137.50M | 119.70M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 629.60M | 641.30M | 684.70M | 972.80M | 391.90M |
Current deferred revenue | 147.70M | 242.30M | 196.50M | 139.20M | 161.50M |
Net debt | 1650.70M | 1697.70M | 1372.00M | 1619.90M | 678.20M |
Short term debt | 263.00M | 223.70M | 230.00M | 183.40M | 0.60M |
Short long term debt | - | - | 5.60M | 9.50M | 6.90M |
Short long term debt total | 1766.00M | 1779.00M | 1442.10M | 1757.40M | 797.90M |
Other stockholder equity | -1497.70000M | -1901.70000M | -1844.00000M | -1934.70000M | -7.60000M |
Property plant equipment | 1243.30M | 1270.90M | 1244.90M | 1043.60M | 327.00M |
Total current assets | 344.30M | 371.80M | 330.90M | 1319.80M | 346.50M |
Long term investments | 7.10M | 5.80M | 5.60M | 1.20M | 0.60M |
Net tangible assets | -464.40000M | -497.90000M | -261.30000M | -188.20000M | -509.30000M |
Short term investments | - | - | - | - | - |
Net receivables | 164.60M | 219.70M | 184.10M | 176.10M | 151.20M |
Long term debt | 562.10M | 606.10M | 258.10M | 810.10M | 797.10M |
Inventory | 32.80M | 49.20M | 35.90M | 26.90M | 22.70M |
Accounts payable | 218.00M | 169.60M | 205.90M | 202.30M | 222.90M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 8.50M | 19.90M | 16.90M | -3.40000M | -7.60000M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | 2672.30M | 2671.10M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | -3.60000M | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | - | - | - | 8.00M | 44.20M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 3308.90M | 3765.00M | 3451.30M | 3246.70M | 3004.30M |
Capital lease obligations | 1203.90M | 1172.90M | 1177.60M | 937.80M | 0.80M |
Long term debt total | 1503.00M | 1555.30M | 1211.30M | 1574.00M | 797.30M |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Investments | 67.30M | -401.70000M | 386.90M | -121.90000M | 9.90M |
Change to liabilities | 44.80M | -33.60000M | -57.60000M | 61.40M | 9.40M |
Total cashflows from investing activities | 67.30M | -401.70000M | 386.90M | -121.90000M | -217.50000M |
Net borrowings | -261.80000M | 131.10M | -758.80000M | -171.40000M | -66.00000M |
Total cash from financing activities | -366.60000M | -176.50000M | -984.70000M | -192.60000M | 125.70M |
Change to operating activities | -31.60000M | 2.50M | 34.40M | 23.80M | -17.20000M |
Net income | -367.80000M | 307.90M | 43.70M | -70.50000M | 55.90M |
Change in cash | 34.00M | 8.60M | -71.80000M | 24.80M | 35.70M |
Begin period cash flow | 81.30M | 72.70M | 144.50M | 119.70M | 84.00M |
End period cash flow | 115.30M | 81.30M | 72.70M | 144.50M | 119.70M |
Total cash from operating activities | 333.30M | 586.80M | 525.90M | 406.90M | 127.60M |
Issuance of capital stock | - | - | - | - | 244.00M |
Depreciation | 262.60M | 265.00M | 237.00M | 246.10M | 68.70M |
Other cashflows from investing activities | 143.40M | -308.20000M | -10.00000M | -26.50000M | -87.70000M |
Dividends paid | 34.30M | 98.10M | 56.30M | 21.20M | 52.30M |
Change to inventory | 14.50M | -12.40000M | -8.90000M | -4.60000M | 0.20M |
Change to account receivables | 52.60M | -33.00000M | 46.10M | -74.40000M | -18.60000M |
Sale purchase of stock | -8.90000M | -139.40000M | -97.50000M | -97.50000M | 244.00M |
Other cashflows from financing activities | -278.40000M | 61.00M | -242.00000M | -171.40000M | 130.00M |
Change to netincome | 431.80M | 40.30M | 127.20M | 179.90M | 42.00M |
Capital expenditures | 76.10M | 93.50M | 61.30M | 72.40M | 100.00M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | 67.10M | -45.40000M | 37.20M | -79.00000M | 1.20M |
Stock based compensation | -7.80000M | 7.90M | 13.70M | 9.60M | - |
Other non cash items | 438.50M | 13.90M | 245.20M | 231.30M | -124.60000M |
Free cash flow | 257.20M | 493.30M | 464.60M | 334.50M | 27.60M |
Sector: Healthcare Industry: Diagnostics & Research
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
HLS Healius Ltd |
-0.06 3.42% | 1.70 | - | 21.10 | 0.52 | 0.84 | 1.43 | -3.5527 |
SHL Sonic Healthcare Ltd |
0.23 0.85% | 27.14 | 24.93 | 17.92 | 1.55 | 1.69 | 1.96 | 10.59 |
IDX Integral Diagnostics Ltd |
-0.03 1.15% | 2.58 | - | 19.12 | 1.22 | 1.85 | 1.97 | 71.46 |
MVF Monash IVF Group Ltd |
-0.025 2.14% | 1.15 | 22.00 | - | 2.40 | 2.05 | 2.89 | 13.15 |
ACL Australian Clinical Labs Ltd |
-0.09 2.71% | 3.23 | 30.00 | 13.35 | 0.75 | 3.09 | 1.22 | 5.27 |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
Liberty Place, Sydney, NSW, Australia, 2000
Name | Title | Year Born |
---|---|---|
Dr. Malcolm W. Parmenter B.S., M.A.I.C.D., M.S. | MD, CEO & Director | 1955 |
Ms. Maxine Jaquet | CFO & COO | NA |
Mr. John McKechnie | Chief Exec. of the Pathology Division | NA |
Mr. Rob Phipps | Group Exec. of People & Culture and Sustainability | NA |
Mr. Henry Barclay | Chief Exec. of Day Hospitals | NA |
Mr. Charles Tilley B.Sc., FCIS, L.L.B., B.Sc. (Hons), LLB (Hons) | Company Sec. | NA |
Ms. Alison Stephenson | Additional Company Sec. | NA |
Ms. Janet Payne | Group Exec. of Corp. Affairs | NA |
Dr. John Houston | Advisor | NA |
Ms. Maxine Jaquet B.Com. | MD, CEO & Director | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.